Thiophene-anthranilamides as highly potent and orally available factor Xa inhibitors

Journal of Medicinal Chemistry

Volumn 50, Issue 13, 2007, Pages 2967-2980

  Ye, Bin ^a   Arnaiz, Damian O ^a   Chou, Yuo Ling ^a   Griedel, Brian D ^a   Karanjawala, Rushad ^a   Lee, Wheeseong ^a   Morrissey, Michael M ^a   Sacchi, Kama L ^a   Sakata, Steven T ^a   Shaw, Kenneth J ^a   Wu, Shung C ^a   Zhao, Zuchun ^a   Adler, Marc ^a   Cheeseman, Sarah ^a   Dole, William P ^a   Ewing, Janice ^a   Fitch, Richard ^a   Lentz, Dao ^a   Liang, Amy ^a   Light, David ^a   Morser, John ^a   Post, Joseph ^a   Rumennik, Galina ^a   Subramanyam, Babu ^a   Sullivan, Mark E ^a   Vergona, Ron ^a   Walters, Janette ^a   Wang, Yi Xin ^a   White, Kathy A ^a   Whitlow, Marc ^a   Kochanny, Monica J ^a   more..

^a BAYER AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINOBENZAMIDE; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A INHIBITOR; THIOPHENE DERIVATIVE; THROMBOPLASTIN; UNCLASSIFIED DRUG; ZK 810388; ZK 813039; ZK 814048;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTICLE; CONTROLLED STUDY; DOG; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG INDICATION; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; HIGH THROUGHPUT SCREENING; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; RAT; VEIN THROMBOSIS; VENOUS STASIS;

AMIDES; AMINOPYRIDINES; ANIMALS; ANTHRANILIC ACIDS; ANTICOAGULANTS; CRYSTALLOGRAPHY, X-RAY; DOGS; FACTOR XA; HUMANS; MALE; MODELS, MOLECULAR; PROTHROMBIN TIME; RATS; RATS, WISTAR; STRUCTURE-ACTIVITY RELATIONSHIP; THIOPHENES; VENOUS THROMBOSIS;

EID: 34347213453     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm070125f     Document Type: Article

References (63)

1. st American Chemical Society National Meeting, April 1-5, 2001, San Diego, CA; American Chemical Society: Washington, DC, 2001; Abstract MEDI-128.
2. st American Chemical Society National Meeting, April 1-5, 2001, San Diego, CA; American Chemical Society: Washington, DC 2001; Abstract MEDI-16.
3. Vlasuk, G. P. Direct factor Xa inhibitors. In New Therapeutic Agents in Thrombosis and Thrombolysis, 1st ed; Sasahara, A. A., Loscalzo, J., Eds.; Marcel Dekker: New York, 1997; pp 261-283.
4. (a) Lefkovits, J.; Topol, E. Direct thrombin inhibitors in cardiovascular medicine. Circulation 1994, 90, 1522-1568.
5. (b) Berry, C. N.; Girardot, C.; Lecoffre, C.; Lunven, C. Effects of synthetic thrombin inhibitor argatroban on fibrin or clot-incorporated thrombin: comparison with heparin and recombinant hirudin. Thromb. Haemost. 1994, 72, 381-386 .
6. (c) Wittig, J. I.; Bourdon, P.; Brezniak, D. V.; Maraganore, J. M.; Fenton, J. W., II. Thrombin-specific inhibition by and slow cleavage of hirulog-1. Biochem. J. 1992, 283, 737-43.
7. (d) Kelly, A. G.; Marzee, W. M.; Krupski, W.; Bass, A.; Cadroy, Y.; Hanson, S. R.; Harker, L. A. Hirudin interruption of heparin-resistant arterial thrombus formation in baboons. Blood 1991, 77, 1006-1012.
8. (a) Stein, P. D.; Grandison, D.; Hua, T. A. Therapeutic level of anticoagulation with Warfarin in patients with mechanical prosthetic heart valves; review of literature and recommendations based on International Normalized Ratio. Postgrad. Med. 1994, 70 (Suppl. 1), S72-S83.
9. (b) Hirsh, J.; Poller, L. The International Normalized Ratio. A guide to understanding and correcting its problems. Arch. Int. Med. 1994, 154, 282-288.
10. (a) Walenga, J. M.; Jeske, W. P.; Hoppensteadt, D.; Fareed, J. Factor Xa inhibitors: Today and beyond. Curr. Opin. Invest. Drugs 2003, 4, 272-281.
11. (b) Kaiser, B. Factor Xa - A promising target for drug development. Cell Mol. Life Sci. 2002, 59, 189-192.
12. (a) Mann, K. G.; Butenas, S.; Brummel, K. The dynamics of thrombin formation. Arterioscler. Thromb. Vasc. Biol. 2003, 23, 17-25.
13. (b) Samama, M. M.; Gerotziafas, G. T. Evaluation of the pharmacological properties and clinical results of the synthetic pentasaccharide (fondaparinux). Thromb. Res. 2003, 109, 1-11.
14. (a) Wong, P. C.; Crain, E. J.; Watson, C. A.; Zaspel, A. M.; Wright, M. R.; Lam, P. Y. S.; Pinto, D. J.; Wexler, R. R.; Knabb, R. M. Nonpeptide factor Xa inhibitors III: Effects of DPC423, an orally-active pyrazole antithrombotic agent, on arterial thrombosis in rabbits. J. Pharmacol. Exp. Ther. 2002, 303, 993-1000.
15. (b) McClanahan, T. B.; Hicks, G. W.; Morrison, A. L.; Peng, Y. W.; Janiczek-Dolphin, N.; Mertz, T. E.; Sullivan, M. E.; Morser, J.; Juneau, P. L.; Leadley, R. The antithrombotic effects of CI-1031 (ZK-807834) and enoxaparin in a canine electrolytic injury model of arterial and venous thrombosis. Eur. J. Pharmacol. 2001, 432, 187-194.
16. (c) Rebello, S. S.; Kasiewski, C. J.; Wang, W.; Bentley, R. G.; Morgan, S. R.; Chu, V.; Colussi, D.; Brown, K.; Perrone, M. H.; Leadley, R. J. Role of short-term inhibition of factor Xa by FXV673 in arterial passivation: A study in a chronic model of thrombosis in conscious dogs. J. Cardiovasc. Pharmacol. 2001, 38, 288-297.
17. (d) Sinha, U.; Ku, P.; Malinowski, J.; Zhu, B. Y.; Scarborough, R. M.; Marlowe, C. K.; Wong, P. W.; Lin, P. H.; Hollenbach, S. J. Antithrombotic and hemostatic capacity of factor Xa versus thrombin inhibitors in models of venous and arteriovenous thrombosis. Eur. J. Pharmacol. 2000, 395, 51-59.
18. (e) Leadley, R. J., Jr.; Morgan, S. R.; Bentley, R.; Bostwick, J. S.; Kasiewski, C. J.; Heran, C.; Chu, V.; Brown, K.; Moxey, P.; Ewing, W. R.; Pauls, H.; Spada, A. P.; Perrone, M. H.; Dunwiddie, C. T. Pharmacodynamic activity and antithrombotic efficacy of RPR120844, a novel inhibitor of coagulation factor Xa. J. Cardiovasc. Pharmacol. 1999, 34, 791-799.
19. (f) Sato, K.; Kawasaki, T.; Hisamichi, N.; Taniuchi, Y.; Hirayama, F.; Koshio, H.; Matsumoto, Y. Antithrombotic effects of YM-60828, a newly synthesized factor Xa inhibitor, in rat thrombosis models and its effects on bleeding time. Br. J. Pharmacol. 1998, 123, 92-96.
20. (a) Leadley, R. J., Jr. Coagulation factor Xa inhibition: Biological background and rationale. Curr. Top. Med. Chem. 2001, 1, 151-159.
21. (b) Hauptmann, J.; Stuerzebecher, J. Synthetic inhibitors of thrombin and factor Xa: From bench to bedside. Thromb. Res. 1999, 93, 203-241.
22. Reviews: (a) Quan, M. L.; Smallheer, J. M. The race to an orally active factor Xa inhibitor: Recent advances. Curr. Opin. Drug Discovery Dev. 2004, 7, 460-469.
23. (b) Gould, W. R.; Leadley, R. J. Recent advances in the discovery and development of direct coagulation factor Xa inhibitors. Curr. Pharm. Des. 2003, 9, 2337-2347.
24. (c) Rai, R.; Sprengler, P. A.; Elrod, K. C.; Young, W. B. Perspectives on factor Xa inhibition. Curr. Med. Chem. 2001, 8, 101-109.
25. (d) Sanderson, P. E. J. Anticoagulants: Inhibitors of thrombin and factor Xa. Ann. Rep. Med. Chem. 2001, 36, 79-88.
26. (e) Zhu, B. Y.; Scarborough, R. M. Factor Xa inhibitors: Recent advances in anticoagulant agents. Ann. Rep. Med. Chem., 2000, 35, 83-102.
27. (f) Vacca, J. P. New advances in the discovery of thrombin and factor Xa inhibitors. Curr. Opin. Chem. Biol. 2000, 4, 394-400.
28. (g) Ewing, W. R.; Pauls, H. W.; Spada, A. P. Progress in the design of inhibitors of coagulation factor Xa. Drugs Future 1999, 24, 771-787.
29. (a) Young, R. J.; Campbell, M.; Borthwick, A. D.; Brown, D.; Burns-Kurtis, C. L.; Chan, C.; Convery, M. A.; Crowe, M. C.; Dayal, S.; Diallo, H.; Kelly, H. A.; King, N. P.; Kleanthous, S.; Mason, A. M.; Mordaunt, J. E.; Patel, C.; Pateman, A. J.; Senger, S.; Shah, G. P.; Smith, P. W.; Watson, N. S.; Weston, H. E.; Zhou, P. Structure- and property-based design of factor Xa inhibitors: Pyrrolidin-2-ones with acyclic alanyl amides as P4 motifs. Bioorg. Med. Chem. Lett. 2006, 16, 5953-5957.
30. (b) Pinto, D. J. P.; Orwat, M. J.; Quan, M. L.; Han, Q.; Galemmo, R. A., Jr.; Amparo, E.; Wells, B.; Ellis, C.; He, M. Y.; Alexander, R. S.; Rossi, K. A.; Smallwood, A.; Wong, P. C.; Luettgen, J.M.; Rendina, A. R.; Knabb, R. M.; Mersinger, L.; Kettner, C.; Bai, S.; He, K.; Wexler, R. R.; Lam, P. Y. S. 1-[3-Aminobenzisoxazol-5′-yl]-3-trifluoromethyl-6-[2′-(3-(R) -hydroxy-N-pyrrolidinyl)methyl-[1,1′]-biphen-4-yl]-1,4,5, 6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one (BMS-740808), a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa. Bioorg. Med. Chem. Lett. 2006, 16, 4141-4147.
31. (c) Roehrig, S.; Straub, A.; Pohlmann, J.; Lampe, T.; Pernerstorfer, J.; Schlemmer, K. H.; Reinemer, P.; Perzborn, E. Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxomorpholin- 4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide (BAY 59-7939): An oral, direct factor Xa inhibitor. J. Med. Chem. 2005, 48, 5900-5908.
32. (d) Quan, M. L.; Lam, P. Y. S.; Han, Q.; Pinto, D. J. P.; He, M. Y.; Li, R.; Ellis, C. D.; Clark, C. G.; Teleha, C. A.; Sun, J. H.; Alexander, R. S.; Bai, S.; Luettgen, J. M.; Knabb, R. M.; Wong, P. C.; Wexler, R. R. Discovery of 1-(3′-Aminobenzisoxazol-5′-yl)-3-trifluoromethyl-N-[2-fluoro- 4-[(2′-dimethylaminomethyl)imidazol-1-yl]phenyl-1H-pyrazole-5- carboxyamide hydrochloride (Razaxaban), a highly potent, selective, and orally bioavailable factor Xa inhibitor. J. Med. Chem. 2005, 48, 1729-1744.
33. (e) Haginoya, N.; Kobayashi, S.; Komoriya, S.; Yoshino, T.; Suzuki, M.; Shimada, T.; Watanabe, K.; Hirokawa, Y.; Furugori, T.; Nagahara, T. Synthesis and conformational analysis of a non-amidine factor Xa inhibitor that incorporates 5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine as S4 binding element. J. Med. Chem. 2004, 47, 5167-5182.
34. (f) Haginoya, N.; Kobayashi, S.; Komoriya, S.; Yoshino, T.; Nagata, T.; Hirokawa, Y.; Nagahara, T. Design, synthesis and biological activity of non-amidine factor Xa inhibitors containing pyridine N-oxide and 2-carbamoylthiazole units. Bioorg. Med. Chem. 2004, 12, 5579-5586.
35. (g) Nazare, M.; Essrich, M.; Will, D. W.; Matter, H.; Ritter, K.; Urmann, M.; Bauer, A.; Schreuder, H.; Dudda, A.; Czech, J.; Lorenz, M.; Laux, V.; Wehner, V. Factor Xa inhibitors based on a 2-carboxyindole scaffold: SAR of neutral P1 substituents. Bioorg. Med. Chem. Lett. 2004, 14, 4191-4195.
36. (h) Nazare, M.; Essrich, M.; Will, D. W.; Matter, H.; Ritter, K.; Urmann, M.; Bauer, A.; Schreuder, H.; Czech, J.; Lorenz, M.; Laux, V.; Wehner, V. Novel factor Xa inhibitors based on a 2-carboxyindole scaffold: SAR of P4 substituents in combination with a neutral P1 ligand. Bioorg. Med. Chem. Lett. 2004, 14, 4197-4201.
37. (i) Zhang, P.; Bao, L.; Zuckett, J. F.; Goldman, E. A.; Jia, Z. J.; Arfsten, A.; Edwards, S.; Sinha, U.; Hutchaleelaha, A.; Park, G.; Lambing, J. L.; Hollenbach, S. J.; Scarborough, R. M.; Zhu, B. Y. Design, synthesis and SAR of anthranilamide-based factor Xa inhibitors incorporating substituted biphenyl P4 motifs. Bioorg. Med. Chem. Lett. 2004, 14, 983-987.
38. (j) Choi-Sledeski, Y. M.; Kearney, R.; Poli, G.; Pauls, H.; Gardner, C.; Gong, Y.; Becker, M.; Davis, R.; Spada, A.; Liang, G.; Chu, V.; Brown, K.; Collussi, D.; Leadley, R., Jr.; Rebello, S.; Moxey, P.; Morgan, S.; Bentley, R.; Kasiewski, C.; Maignan, S.; Guilloteau, J.-P.; Mikol, V. Discovery of an orally efficacious inhibitor of coagulation factor Xa which incorporates a neutral P1 ligand. J. Med. Chem. 2003, 46, 681-684.
39. (k) Masters, J. J.; Franciskovich, J. B.; Tinsley, J. M.; Campbell, C.; Craft, T. J.; Froelich, L. L.; Gifford-Moore, D. S.; Hay, L. A.; Herron, D. K.; Klimkowski, V. J.; Kurz, K. D.; Metz, J. T.; Ratz, A. M.; Shuman, R. T.; Smith, G. F.; Smith, T.; Towner, R. D.; Wiley, M. R.; Wilson, A.; Yee, Y. K. Non-amidine-containing 1,2-dibenzamidobenzene inhibitors of human factor Xa with potent anticoagulant and antithrombotic activity. J. Med. Chem. 2000, 43, 2087-2092.
40. (l) Herron, D. K.; Goodson, T., Jr.; Wiley, M. R.; Weir, L. C.; Kyle, J. A.; Yee, Y. K.; Tebbe, A. L.; Tinsley, J. M.; Mendel, D.; Masters, J. J.; Franciskovich, J. B.; Sawyer, J. S.; Beight, D. W.; Ratz, A. M.; Milot, G.; Hall, S. E.; Klimkowski, V. J.; Wikel, J. H.; Eastwood, B. J.; Towner, R. D.; Gifford-Moore, D. S.; Craft, T. J.; Smith, G. F. 1,2-Dibenzamidobenzene inhibitors of human factor Xa. J. Med. Chem. 2000, 43, 859-872.
41. (a) Chou, Y. L.; Davey, D. D.; Eagen, K. A.; Griedel, B. D.; Karanjawala, R.; Phillips, G. B.; Sacchi, K. L.; Shaw, K. J.; Wu, S. C.; Lentz, D.; Liang, A.; Trinh, L.; Morrissey, M. M.; Kochanny, M. J. Structure-activity relationships of substituted benzothiophene-anthranilamide factor Xa inhibitors. Bioorg. Med. Chem. Lett. 2003, 13, 507-511.
42. (b) Liang, A. M.; Light, D. R.; Kochanny, M.; Trinh, L.; Rumennik, G.; Lentz, D.; Post, J.; Morser, J.; Snider, M. Discovery and characterization of a potent and selective non-amidine inhibitor of human factor Xa. Biochem. Pharmacol. 2003, 65, 1407-1418.
43. Kochanny, M. J.; Adler, M.; Ewing, J.; Griedel, B. D.; Ho, E.; Karanjawala, R.; Lee, W.; Lentz, D.; Liang, A. M.; Morrissey, M. M.; Phillips, G. B.; Post, J.; Sacchi, K. L.; Sakata, S. T.; Subramanyam, B.; Vergona, R.; Walters, J.; White, K. A.; Whitlow, M.; Ye, B.; Zhao, Z.; Shaw, K. J. Substituted thiophene-anthranilamides as potent inhibitors of human factor Xa. Bioorg. Med. Chem. 2007, 15, 2127-2146.
44. 2-Aroylanthramlamide inhibitors of human factor Xa. J. Med. Chem. 2000, 43, 873-882.
45. (b) Shrader, W. D.; Young, W. B.; Sprengeler, P. A.; Sangalang, J. C.; Elrod, K.; Carr, G. Neutral inhibitors of the serine protease factor Xa. Bioorg. Med. Chem. Lett. 2001, 11, 1801-1804.
46. (c) Zhang, P.; Bao, L.; Zuckett, J. F.; Jia, Z. J.; Woolfrey, J.; Arfsten, A.; Edwards, S.; Sinha, U.; Hutchaleelaha, A.; Lambing, J. L.; Hollenbach, S. J.; Scarborough, R. M.; Zhu, B. Y. Design, synthesis and SAR of anthranilamide-based factor Xa inhibitors with improved functional activity. Bioorg. Med. Chem. Lett. 2004, 14, 989-993.
47. See references 10i, 10k, 11a, 12, 13c, and the following: (a) Tucker, T. J.; Lumma, W. C.; Lewis, S. D.; Gardell, S. J.; Lucas, B. J.; Baskin, E. P.; Woltmann, R.; Lynch, J. J.; Lyle, E. A.; Appleby, S. D.; Chen, I.-W.; Dancheck, K. B.; Vacca, J. P. Potent noncovalent thrombin inhibitors that utilize the unique amino acid D-dicyclohexylalanine in the P3 position. Implications on oral bioavailability and antithrombotic efficacy. J. Med. Chem. 1997, 40, 1565-1569.
48. (b) Tucker, T. J.; Brady, S. F.; Lumma, W. C.; Lewis, S. D.; Gardell, S. J.; Naylor-Olsen, A. M.; Yan, Y.; Sisko, J. T.; Stauffer, K. J.; Lucas, B. J.; Lynch, J. J.; Cook, J. J.; Stranieri, M. T.; Holahan, M. A.; Lyle, E. A.; Baskin, E. P.; Chen, I. W.; Dancheck, K. B.; Krueger, J. A.; Cooper, C. M.; Vacca, J. P. Design and synthesis of a series of potent and orally bioavailable noncovalent thrombin inhibitors that utilize nonbasic groups in the P1 position. J. Med. Chem. 1998, 41, 3210-3219.
49. Aurell, L.; Friberger, P.; Karlsson, G.; Claeson, G. A new sensitive and highly specific chromogenic peptide substrate for factor Xa. Thromb. Res. 1977, 11, 595-609.
50. Although this method has a shortcoming in that active metabolites could alter results, the speed at which we were able to generate data to influence the design process outweighed this shortcoming.
51. Arnaiz, D. O.; Chou, Y. L.; Griedel, B. D.; Karanjawala, R. E.; Kochanny, M. J.; Lee, W.; Liang, A. M.; Morrissey, M. M.; Phillips, G. B.; Sacchi, K. L.; Sakata, S. T.; Shaw, K. J.; Snider, R. M.; Wu, S. C.; Ye, B.; Zhao, Z. ortho-Anthranilamide derivatives as anticoagulants. U.S. Patent 6,140,351, October 31, 2000.
52. See reference 10c and the following: (a) Maignan, S.; Guilloteau, J. P.; Choi-Sledeski, Y. M.; Becker, M. R.; Ewing, W. R.; Pauls, H. W.; Spada, A. P.; Mikol, V. Molecular structures of human factor Xa complexed with ketopiperazine inhibitors: Preference for a neutral group in the S1 pocket. J. Med. Chem. 2003, 46, 685-690.
53. (b) Nazare, M.; Will, D. W.; Matter, H.; Schreuder, H.; Ritter, K.; Urmann, M.; Essrich, M.; Bauer, A.; Wagner, M.; Czech, J.; Lorenz, M.; Laux, V.; Wehner, V. Probing the subpockets of factor Xa reveals two binding modes for inhibitors based on a 2-carboxyindole scaffold: A study combining structure-activity relationship and X-ray crystallography. J. Med. Chem. 2005, 48, 4511-4525.
54. (c) Kohrt, J. T.; Filipiski, K. J.; Cody, W. L.; Bigge, C. F.; La, F.; Welch, K.; Dahring, T.; Bryant, J. W.; Leonard, D.; Bolton, G.; Narasimhan, L.; Zhang, E.; Peterson, J. T.; Haarer, S.; Sahasrabudhe, V.; Janiczek, N.; Desiraju, S.; Hena, M.; Fiakpui, C.; Saraswat, N.; Sharma, R.; Sun, S.; Maiti, S. N.; Leadley, R.; Edmunds, J. J. The discovery of glycine and related amino acid-based factor Xa inhibitors. Bioorg. Med. Chem. 2006, 14, 4379-4392.
55. Stubbs, M. T.; Reyda, S.; Dullweber, F.; Moller, M.; Klebe, G.; Dorsch, D.; Mederski, W. W.; Wurziger, H. pH-Dependent binding modes observed in trypsin crystals: Lessons for structure-based drug design. ChemBioChem 2002, 3, 246-249.
56. (a) Katz, B. A.; Sprengeler, P. A.; Luong, C.; Verner, E.; Elrod, K.; Kirtley, M.; Jane, J.; Spencer, J. R.; Breitenbucher, J. G.; Hui, H.; McGee, D.; Allen, D.; Martelli, A.; Mackman, R. L. Engineering inhibitors highly selective for the S1 sites of Ser190 trypsin-like serine protease drug targets. Chem. Biol. 2001, 8, 1107-1121.
57. (b) Mackman, R. L.; Katz, B. A.; Breitenbucher, J. G.; Hui, H. C.; Verner, E.; Luong, C.; Liu, L.; Sprengeler, P. A. Exploiting subsite S1 of trypsin-like serine proteases for selectivity: Potent and selective inhibitors of urokinase-type plasminogen activator. J. Med. Chem. 2001, 44, 3856-3871.
58. A detailed discussion of the crystal structure of compound 13a bound to fXa is described elsewhere: Adler, M.; Kochanny, M. J.; Ye, B.; Rumennik, G.; Light, D. R.; Biancalana, S.; Whitlow, M. Crystal structures of two potent nonamidine inhibitors bound to factor Xa. Biochemistry 2002, 41, 15514-15523.
59. (a) Maignan, S.; Mikol, V. The use of 3D structure data in the design of specific factor Xa inhibitors. Curr. Top. Med. Chem. 2001, 1, 161-174.
60. (b) Adler, M.; Davey, D. D.; Phillips, G. B.; Kim, S.-H.; Jancarik, J.; Rumennik, G.; Light, D. R.; Whitlow, M. Preparation, characterization, and the crystal structure of the inhibitor ZK-807834 (CI-1031) complexed with factor Xa. Biochemistry 2000, 39, 12534-12542.
61. Lottenberg, R.; Christensen, U.; Jackson, C. M.; Coleman, P. L. Assay of coagulation proteases using peptide chromogenic and fluorogenic substrates. Methods Enzymol. 1981, 80, 341-361.
62. (a) Jordan, S. P.; Waxman, L.; Smith, D. E.; Vlasuk, G. P. Tick anticoagulant peptide: kinetic analysis of the recombinant inhibitor with blood coagulation factor Xa. Biochem. 1990, 29, 11095-11100.
63. (b) Morrison, J. F. Kinetics of the reversible inhibition of enzyme-catalysed reactions by tight-binding inhibitors. Biochim. Biophys. Acta 1969, 185, 269-286.